More than 100 vaccines are being developed globally, including
several already in human trials from the likes of AstraZeneca <AZN.L>
and Pfizer <PFE.N>, to try and control a disease that has infected
more than 8 million people and killed over 430,000 worldwide.
The vaccine being evaluated by Singapore's Duke-NUS Medical School
works on the relatively-untested Messenger RNA (mRNA) technology,
which instructs human cells to make specific coronavirus proteins
that produce an immune response.
"The fact that it replicates and triggers a very balanced immune
response, both in terms of the antibody and killer cells - those are
welcome properties," Ooi Eng Eong, deputy director of the school's
emerging infectious diseases programme, told Reuters on Tuesday.
Antibodies stick to the virus and prevent it from infecting cells,
while killer cells, another arm of the immune system, recognise
infected cells and destroy them, he said.
The mRNA approach has not yet been approved for any medicine so its
backers, which also include U.S. biotech firm Moderna <MRNA.O>, are
treading uncharted territory.
Because of that, Ooi said longer studies were needed to ensure its
safety.
[to top of second column] |
"The most optimistic case is that it's about this time next year,
that we will have a vaccine," Ooi said.
Ooi is also working on a monoclonal antibody treatment for COVID-19
and will begin safety trials on healthy people this week, before
testing on COVID-19 patients in the coming months.
Ooi said potential deployment of the treatment could be faster than
the vaccine, without giving an exact timeline.
Antibodies are generated in the body to fight off infection.
Monoclonal antibodies mimic natural antibodies and can be isolated
and manufactured in large quantities to treat diseases.
Tiny city-state Singapore has one of the highest infection tallies
in Asia, with more than 40,000 cases, largely due to mass outbreaks
in dormitories for its migrant workers.
(Reporting by Aradhana Aravindan in Singapore; Editing by Himani
Sarkar)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |